Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update

Workgroup Chair and Cochair

doi:10.1016/j.anai.2017.08.012

Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update

Workgroup Chair and Cochair

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	489-511.e41
Journal	Annals of Allergy, Asthma and Immunology
Volume	119
Issue number	6
DOIs	https://doi.org/10.1016/j.anai.2017.08.012
State	Published - Dec 2017

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Immunology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.anai.2017.08.012

Cite this

@article{7b8fe5e9064f4c5da3577dd04197163d,

title = "Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update",

author = "{Workgroup Chair and Cochair} and Dykewicz, {Mark S.} and Wallace, {Dana V.} and Fuad Baroody and Jonathan Bernstein and Tim Craig and Ira Finegold and Faith Huang and Desiree Larenas-Linnemann and Eli Meltzer and Gary Steven and Bernstein, {David I.} and Joann Blessing-Moore and Chitra Dinakar and Matthew Greenhawt and Horner, {Caroline C.} and Khan, {David A.} and David Lang and John Oppenheimer and Portnoy, {Jay M.} and Randolph, {Christopher R.} and Rank, {Matthew A.} and Dykewicz, {Mark S.} and Wallace, {Dana V.}",

note = "Funding Information: Funding Sources: This work was funded by the American Academy of Allergy, Asthma, Immunology and the American College of Allergy, Asthma, and Immunology. Funding Information: Thirteen studies are reported as single trials. 65-77 One meta-analysis reported study findings from 3 trials, one of which was also included as a single trial 76 already included in this analysis and therefore was not repeated. Twelve of the studies were randomized, double-blind, placebo-controlled, parallel-group trials, 65,67-78 and one study used a double-blind, placebo-controlled, crossover study design. 66 The measures used in the studies are found in Appendix B , Table 1 . Five studies 65,71,72,74,78 disclosed and met the needed sample size to determine significant findings, whereas the remaining studies did not report this value or did not obtain the needed study participants. One study 66 was funded by a grant from the Asthma and Allergy Research Group, whereas the remaining studies received funding from pharmaceutical companies or the members of the study teams were or had been a consultant or speaker for a pharmaceutical company or employees of a pharmaceutical company. ",

year = "2017",

month = dec,

doi = "10.1016/j.anai.2017.08.012",

language = "English (US)",

volume = "119",

pages = "489--511.e41",

journal = "Annals of Allergy, Asthma and Immunology",

issn = "1081-1206",

publisher = "American College of Allergy, Asthma and Immunology",

number = "6",

}

TY - JOUR

T1 - Treatment of seasonal allergic rhinitis

T2 - An evidence-based focused 2017 guideline update

AU - Workgroup Chair and Cochair

AU - Dykewicz, Mark S.

AU - Wallace, Dana V.

AU - Baroody, Fuad

AU - Bernstein, Jonathan

AU - Craig, Tim

AU - Finegold, Ira

AU - Huang, Faith

AU - Larenas-Linnemann, Desiree

AU - Meltzer, Eli

AU - Steven, Gary

AU - Bernstein, David I.

AU - Blessing-Moore, Joann

AU - Dinakar, Chitra

AU - Greenhawt, Matthew

AU - Horner, Caroline C.

AU - Khan, David A.

AU - Lang, David

AU - Oppenheimer, John

AU - Portnoy, Jay M.

AU - Randolph, Christopher R.

AU - Rank, Matthew A.

AU - Dykewicz, Mark S.

AU - Wallace, Dana V.

N1 - Funding Information: Funding Sources: This work was funded by the American Academy of Allergy, Asthma, Immunology and the American College of Allergy, Asthma, and Immunology. Funding Information: Thirteen studies are reported as single trials. 65-77 One meta-analysis reported study findings from 3 trials, one of which was also included as a single trial 76 already included in this analysis and therefore was not repeated. Twelve of the studies were randomized, double-blind, placebo-controlled, parallel-group trials, 65,67-78 and one study used a double-blind, placebo-controlled, crossover study design. 66 The measures used in the studies are found in Appendix B , Table 1 . Five studies 65,71,72,74,78 disclosed and met the needed sample size to determine significant findings, whereas the remaining studies did not report this value or did not obtain the needed study participants. One study 66 was funded by a grant from the Asthma and Allergy Research Group, whereas the remaining studies received funding from pharmaceutical companies or the members of the study teams were or had been a consultant or speaker for a pharmaceutical company or employees of a pharmaceutical company.

PY - 2017/12

Y1 - 2017/12

UR - http://www.scopus.com/inward/record.url?scp=85034986939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034986939&partnerID=8YFLogxK

U2 - 10.1016/j.anai.2017.08.012

DO - 10.1016/j.anai.2017.08.012

M3 - Article

C2 - 29103802

AN - SCOPUS:85034986939

SN - 1081-1206

VL - 119

SP - 489-511.e41

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

IS - 6

ER -

Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this